KFDA approves extension of license indication for Eliquis

The Korea Food and Drug Administration on Tuesday approved a new indication for Eliquis (apixaban) 2.5mg tablets as follows:

“Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 80 years; weight ≤60kg or serum creatinine ≥1.5 mg/dL (133 micromol...